The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On May 13, oral VK2735 demonstrated up to 12.2% mean weight reduction from baseline at Week 13 in Phase 2 trials. This announcement led to a gain in shares for Viking Therapeutics.